Business Description
Zevra Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US4884451075
Description
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With unique, data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.55 | |||||
| Equity-to-Asset | 0.36 | |||||
| Debt-to-Equity | 0.71 | |||||
| Debt-to-EBITDA | -1.01 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -2.81 | |||||
| Beneish M-Score | -1.12 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -38.5 | |||||
| 3-Year EBITDA Growth Rate | 3.4 | |||||
| 3-Year EPS without NRI Growth Rate | 23.7 | |||||
| 3-Year FCF Growth Rate | -24.4 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 33.95 | |||||
| 9-Day RSI | 30.36 | |||||
| 14-Day RSI | 31.93 | |||||
| 6-1 Month Momentum % | 34.27 | |||||
| 12-1 Month Momentum % | -1.71 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.18 | |||||
| Quick Ratio | 1.18 | |||||
| Cash Ratio | 0.92 | |||||
| Days Sales Outstanding | 139.97 | |||||
| Days Payable | 1086.86 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -109.2 | |||||
| Shareholder Yield % | -7.65 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 89.28 | |||||
| Operating Margin % | -180.63 | |||||
| Net Margin % | -167.69 | |||||
| FCF Margin % | -123.2 | |||||
| ROE % | -66.86 | |||||
| ROA % | -36.05 | |||||
| ROIC % | -112.22 | |||||
| ROC (Joel Greenblatt) % | -2862.25 | |||||
| ROCE % | -44.78 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 6.21 | |||||
| PB Ratio | 3.07 | |||||
| EV-to-EBIT | -3.76 | |||||
| EV-to-Forward-EBIT | -2.97 | |||||
| EV-to-EBITDA | -3.84 | |||||
| EV-to-Forward-EBITDA | -3.37 | |||||
| EV-to-Revenue | 6.09 | |||||
| EV-to-Forward-Revenue | 5.28 | |||||
| EV-to-FCF | -4.94 | |||||
| Earnings Yield (Greenblatt) % | -26.6 | |||||
| FCF Yield % | -17.65 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ZVRA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Zevra Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 27.461 | ||
| EPS (TTM) ($) | -1.29 | ||
| Beta | 0.72 | ||
| Volatility % | 48.88 | ||
| 14-Day RSI | 31.93 | ||
| 14-Day ATR ($) | 0.255066 | ||
| 20-Day SMA ($) | 4.96 | ||
| 12-1 Month Momentum % | -1.71 | ||
| 52-Week Range ($) | 3.89 - 7.28 | ||
| Shares Outstanding (Mil) | 41.85 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Zevra Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Zevra Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Zevra Therapeutics Inc Frequently Asked Questions
What is Zevra Therapeutics Inc(ZVRA)'s stock price today?
The current price of ZVRA is $4.59. The 52 week high of ZVRA is $7.28 and 52 week low is $3.89.
When is next earnings date of Zevra Therapeutics Inc(ZVRA)?
The next earnings date of Zevra Therapeutics Inc(ZVRA) is 2024-05-15 Est..
Does Zevra Therapeutics Inc(ZVRA) pay dividends? If so, how much?
Zevra Therapeutics Inc(ZVRA) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers